Chronic inflammatory response in the rat can be blocked by bindarit

Area of Science:

• Immunology and Biochemistry
• Pharmacology and Drug Discovery

Background:

• Chronic inflammation, induced by Freund's complete adjuvant in rats, elevates acute-phase proteins like alpha 2-macroglobulin and alters plasma protein Con A-reactivity.
• Bindarit, a compound known to inhibit protein denaturation and reduce arthritis response, was investigated for its effects on these inflammatory markers.

Purpose of the Study:

• To evaluate the effect of bindarit on the expression of alpha 2-macroglobulin in rats with adjuvant-induced chronic inflammation.
• To assess bindarit's impact on concanavalin A (Con A)-reactivity of plasma proteins during chronic inflammation.

Main Methods:

• Adult rats were induced with chronic inflammation using Freund's complete adjuvant.
• Bindarit was administered via a medicated diet, with indomethacin used as a reference drug.
• Alpha 2-macroglobulin concentration and Con A-reactivity of proteins were analyzed using radioimmunoassay, lectin-blots, and immuno-blots.

Main Results:

• Adjuvant-induced arthritis significantly increased alpha 2-macroglobulin concentration and Con A-reactivity in rat plasma.
• Both bindarit and indomethacin treatments reduced alpha 2-macroglobulin levels and Con A-reactivity to normal levels within 37 days.
• Chronic inflammation did not significantly alter concentrations of clusterin or testibumin.

Conclusions:

• Bindarit effectively mitigates key biochemical changes associated with chronic inflammation in rats, including elevated alpha 2-macroglobulin and altered protein glycosylation.
• The findings support bindarit's potential as a tool to investigate the link between abnormal glycosylation, protein denaturation, and autoimmune diseases.